Biorem Inc

Biorem's capital structure shows a debt-to-equity ratio of 0.55, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.62, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is minimal at 51,690 CAD, and its operating cash flow of 4,178,040 CAD is partially offset by capital expenditures of -363,110 CAD.

In terms of profitability, Biorem's return on equity (ROE) is 4.63%, and its return on assets (ROA) is 1.55%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of generating returns from equity and total assets.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks if demand in its primary market fluctuates.

Looking at the growth trajectory, Biorem's revenue for the latest period is 5,917,900 CAD. While the company has shown positive net income of 341,130 CAD, there is no provided outlook for the next fiscal year to assess future growth potential. The absence of a clear growth trajectory makes it difficult to evaluate the company's long-term prospects.

The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could impact its ability to meet short-term obligations without additional financing. No dilution risk is flagged, suggesting that the company is not expected to issue additional shares in the near term.

Recent events, as reflected in the financial data, show that Biorem has maintained a consistent number of shares outstanding, with no recent changes in the basic or diluted share count. Analysts have provided a mean price target of 3.50 CAD, with a single "buy" recommendation and no "strong buy" or "hold" ratings.

Biorem demonstrates best-in-class cash conversion at 12.25, vastly outperforming the 0.95 cohort median.

The single analyst consensus price target of $3.50 implies 12.2% upside from the current market price.

Biorem faces high credit risk, signaling potential difficulties in meeting financial obligations or securing financing.

The debt-to-equity ratio of 0.55 is higher than the 0.43 cohort median, suggesting elevated leverage.

Medium liquidity risk flags potential challenges in meeting short-term financial obligations or operational needs.

Net income has declined 8.0% annually over the past four years, showing deteriorating bottom-line performance.

Revenue C$16.9M, +81,9% YoY; Operating income +1 201,3% YoY.

• ▍Revenue C$16.9M, +81,9% YoY
• ▍Operating income +1 201,3% YoY
• ▍Net income +1 585,1% YoY
• ▍Free cash flow +863,5% YoY
• ▍Net margin 17.0%

Revenue C$11.3M, −24,4% YoY; Operating income −46,8% YoY.

• ▍Revenue C$11.3M, −24,4% YoY
• ▍Operating income −46,8% YoY
• ▍Net income −47,2% YoY
• ▍Free cash flow −45,7% YoY
• ▍Net margin 10.3%

Revenue C$9.4M, +29,2% YoY; Operating income +105,6% YoY.

• ▍Revenue C$9.4M, +29,2% YoY
• ▍Operating income +105,6% YoY
• ▍Net income +119,2% YoY
• ▍Free cash flow +47,2% YoY
• ▍Net margin 7.9%

Revenue C$4.7M, −20,1% YoY; Operating income −81,7% YoY.

• ▍Revenue C$4.7M, −20,1% YoY
• ▍Operating income −81,7% YoY
• ▍Net income −89,1% YoY
• ▍Free cash flow +56,2% YoY
• ▍Net margin 0.8%

Revenue C$9.3M; Operating income C$286.6k.

• ▍Revenue C$9.3M
• ▍Operating income C$286.6k
• ▍Net margin 1.8%

Revenue C$42.4M, +13,2% YoY; Operating income +49,4% YoY.

• ▍Revenue C$42.4M, +13,2% YoY
• ▍Operating income +49,4% YoY
• ▍Net income +58,2% YoY
• ▍Free cash flow +56,4% YoY
• ▍Net margin 11.4%

Revenue C$37.4M, +48,7% YoY; Operating income +41,8% YoY.

• ▍Revenue C$37.4M, +48,7% YoY
• ▍Operating income +41,8% YoY
• ▍Net income +39,7% YoY
• ▍Free cash flow +56,5% YoY
• ▍Net margin 8.1%